Advertisement

Journal of Neurology

, Volume 265, Issue 9, pp 2005–2014 | Cite as

Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson’s disease and their caregivers

  • Rosella CiurleoEmail author
  • Francesco Corallo
  • Lilla Bonanno
  • Viviana Lo Buono
  • Giuseppe Di Lorenzo
  • Roberta Versaci
  • Cettina Allone
  • Rosanna Palmeri
  • Placido Bramanti
  • Silvia Marino
Original Communication

Abstract

The gold standard of treatment in Parkinson’s disease (PD) is levodopa/carbidopa whose long-term use induces motor and non-motor fluctuations and dyskinesias. Continuous infusion of intrajejunal levodopa/carbidopa intestinal gel (Duodopa®) reduces motor and non-motor symptoms and dyskinesias, and improves the quality of life of patients. The aim of this open observational prospective study was to evaluate the impact of Duodopa® on conditions of PD patients and caregivers, and their quality of life. We enrolled 12 patients with advanced PD and their caregivers. The PD patients were assessed at baseline, 3 and 6 months after Duodopa® treatment initiation using Unified Parkinson’s Disease Rating Scale-Part III and IV (UPDRS-III and IV), Unified Dyskinesia Rating Scale (UdysRS), Beck Depression Inventory (BDI-II), Hamilton Anxiety Rating Scale (HAM-A) and Parkinson’s Disease Quality of Life Questionnaire (PDQ-39). The caregivers were assessed, at the same time as the patients, using BDI-II, HAM-A, Caregiver Burden Inventory (CBI) and SF-36 Health Status Questionnaire. Six months after Duodopa® therapy, the scores of UPDRS-III and IV, UdysRS, BDI-II, HAM-A and PDQ-39 were significantly decreased (p < 0.01). After Duodopa® therapy, in caregiver group the scores of BDI-II, HAM-A and CBI were significantly decreased and the scores of SF-36 Health Status Questionnaire were significantly increased (p < 0.01). A reduction of anxiety after therapy correlated with mental status domains of SF-36 Health Status Questionnaire (r = 0.56). Overall, Duodopa® is effective even in the short time to improve the clinical conditions of PD patients and caregivers and their quality of life.

Keywords

Duodopa® Parkinson’s disease Quality of life Caregiver Dyskinesias 

Notes

Author contributions

RC: Concept, design, definition of intellectual content, literature search, manuscript preparation. FC: Concept, design, definition of intellectual content, literature search, data acquisition. LB: Data analysis. VLB: Data acquisition. GDL: Data acquisition. RV: Data acquisition. CA: Data acquisition. RP: Data acquisition. PB: Design, definition of intellectual content. SM: Definition of intellectual content, manuscript editing and review.

Compliance with ethical standards

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical standard

The study including human participants has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

References

  1. 1.
    Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N et al (2000) Pathophysiology of the basal ganglia in Parkinson’s disease. Trends Neurosci 23:S8–S19CrossRefPubMedGoogle Scholar
  2. 2.
    Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M et al (2011) The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S2–S41.  https://doi.org/10.1002/mds.23829 CrossRefPubMedGoogle Scholar
  3. 3.
    Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias s and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458.  https://doi.org/10.1002/mds.1090 CrossRefPubMedGoogle Scholar
  4. 4.
    Gunal DI, Nurichalichi K, Tuncer N, Bekiroglu N, Aktan S (2002) The clinical profile of nonmotor fluctuation in Parkinson’s disease patients. Can J Neurol Sci 29:61–64CrossRefPubMedGoogle Scholar
  5. 5.
    Cedarbaum JM (1987) Clinical pharmacokinetics of anti-Parkinsonian drugs. Clin Pharmacokinet 13:141–178CrossRefPubMedGoogle Scholar
  6. 6.
    Nutt JG (2008) Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 23:S580–S584.  https://doi.org/10.1002/mds.22037 CrossRefPubMedGoogle Scholar
  7. 7.
    Mouradian MM, Juncos JL, Fabrini G, Chase TN (1989) Motor fluctuations in Parkinson’s disease. Ann Neurol 25:633–634CrossRefGoogle Scholar
  8. 8.
    Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:337–345Google Scholar
  9. 9.
    Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F (2005) Impact of the motor complications of Parekinson’s disease on the quality of life. Mov Disord 20:224–230.  https://doi.org/10.1002/mds.20279 CrossRefPubMedGoogle Scholar
  10. 10.
    Storch A, Schneider CB, Wolz M, Stürwald Y, Nebe A, Odin P et al (2013) Nonmotor fluctuations in Parkinson desease: severity and correlation with motor complications. Neurology 80:800–809.  https://doi.org/10.1212/WNL.0b013e318285c0ed CrossRefPubMedGoogle Scholar
  11. 11.
    Palmeri R, Lo Buono V, Corallo F, Foti M, Di Lorenzo G, Bramanti P et al (2017) Nonmotor symptoms in Parkinson disease: a descriptive review on social cognition ability. J Ger Psych Neurol 30:109–121.  https://doi.org/10.1177/0891988716687872 CrossRefGoogle Scholar
  12. 12.
    Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J et al (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–441CrossRefPubMedGoogle Scholar
  13. 13.
    Martinez-Martin P, Forijaz MJ, Frades-Pyo B, Rusiñol AB, Fernández-García JM, Benito-León J et al (2007) Caregiver burden in Parkinson’s disease. Mov Disord 22:924–931.  https://doi.org/10.1002/mds.21355 CrossRefPubMedGoogle Scholar
  14. 14.
    Martinez-Martin P, Arroyo S, Rojo-Abuin JM, Rodriguez-Blazquez C, Frades B, de Pedro Cuesta J (2008) Longitudinal Parkinson’s Disease Patient Study (Estudio longitudinal de pacientes con enfermedad de Parkinson-ELEP) Group. Burden, perceived health status, and mood among caregivers of Parkinson’s disease patients. Mov Disord 23:1673–1680.  https://doi.org/10.1002/mds.22106 CrossRefPubMedGoogle Scholar
  15. 15.
    Rascol O, Perez-Lloret S, Ferreira JJ (2015) New treatments for levodopa-induced motor complications. Mov Disord 30:1451–1460.  https://doi.org/10.1002/mds.26362 CrossRefPubMedGoogle Scholar
  16. 16.
    LeWitt PA (2016) New levodopa therapeutic strategies. Parkinsonism Relat Disord 22:S37–S40.  https://doi.org/10.1016/j.parkreldis.2015.09.021 CrossRefPubMedGoogle Scholar
  17. 17.
    Politis M, Sauerbier A, Loane C, Pavese N, Martin A, Corcoran B et al (2017) Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson’s disease patients. Mov Disord 32:235–240.  https://doi.org/10.1002/mds.26848 CrossRefPubMedGoogle Scholar
  18. 18.
    De Fabregues O, Dot J, Abu-Suboh M, Hernández-Vara J, Ferré A, Romero O et al (2017) Long-term safety and effectiveness of levodopa–carbidopa intestinal gel infusion. Brain Behav 7:e00758.  https://doi.org/10.1002/brb3.758 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z et al (2017) Levodopa–carbidopa intestinal gel in advanced Parkinson’s: Final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20.  https://doi.org/10.1016/j.parkreldis.2017.09.018 CrossRefPubMedGoogle Scholar
  20. 20.
    Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L et al (2007) Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord 22:1145–1149.  https://doi.org/10.1002/mds.21500 CrossRefPubMedGoogle Scholar
  21. 21.
    Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L et al (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson’s disease. Neurodegener Dis 5:244–246.  https://doi.org/10.1159/000113714 CrossRefPubMedGoogle Scholar
  22. 22.
    Antonini A, Yegin A, Preda C, Bergmann L, Poewe W, GLORIA study Investigators and Coordinators (2015) Global long-term study on motor and non-motor symptoms and safety of levodopa–carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord 21:231–235.  https://doi.org/10.1016/j.parkreldis.2014.12.012 CrossRefPubMedGoogle Scholar
  23. 23.
    Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R et al (2008) Continuous jejunal levodopa infusion in patients with advanced Parkinson’s disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 31:151–166.  https://doi.org/10.1097/wnf.0b013e31814b113e CrossRefPubMedGoogle Scholar
  24. 24.
    Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474.  https://doi.org/10.1002/mds.22596 CrossRefPubMedGoogle Scholar
  25. 25.
    Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J et al (2012) Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126:29–33.  https://doi.org/10.1111/j.1600-0404.2012.01689.x CrossRefGoogle Scholar
  26. 26.
    Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L et al (2013) Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study. J Neurol 260:105–114.  https://doi.org/10.1007/s00415-012-6597-0 CrossRefPubMedGoogle Scholar
  27. 27.
    Zibetti M, Merola A, Artusi CA, Rizzi L, Angrisano S, Reggio D et al (2014) Levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease: a 7-year experience. Eur J Neurol 21:312–318.  https://doi.org/10.1111/ene.12309 CrossRefPubMedGoogle Scholar
  28. 28.
    Foltynie T, Magee C, James C, Webster GJ, Lees AJ, Limousin P (2013) Impact of duodopa on quality of life in advanced Parkinson’s disease: a UK case series. Parkinsons Dis 2013:362908.  https://doi.org/10.1155/2013/362908 PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Bohlega S, Abou Al-Shaar H, Alkhairallah T, Al-Ajlan F, Hasan N, Alkahtani K (2015) Levodopa–carbidopa intestinal gel infusion therapy in advanced Parkinson’s disease: single middle eastern center experience. Eur Neurol 74:227–236.  https://doi.org/10.1159/000442151 CrossRefPubMedGoogle Scholar
  30. 30.
    Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F et al (2015) Levodopa–carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month. Open-label results. Mov Disord 30:500–509.  https://doi.org/10.1002/mds.26123 CrossRefPubMedGoogle Scholar
  31. 31.
    Bellante F, Dethy S, De Beyl DZ (2016) Depression, anxiety and non-motor symptoms on initiation ogf intrajejunal levodopa/carbodopa therapy. Acta Neurol Belg 116:39–41.  https://doi.org/10.1007/s13760-015-0497-x CrossRefPubMedGoogle Scholar
  32. 32.
    Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N (2012) Intrajejunal levodopa infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patients’ and caregivers’ quality of life. Eur Rev Med Pharmacol Sci 16:79–89PubMedGoogle Scholar
  33. 33.
    Santos-García D, Añón MJ, Fuster-Sanjurjo L, de la Fuente-Fernández R (2012) Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson’s disease leads to improvement in caregivers’ stress and burden. Eur J Neurol 19:1261–1265.  https://doi.org/10.1111/j.1468-1331.2011.03630.x CrossRefPubMedGoogle Scholar
  34. 34.
    Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Movement Disorder Society UPDRS Revision Task Force et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23:2129–2170.  https://doi.org/10.1002/mds.22340 CrossRefPubMedGoogle Scholar
  35. 35.
    Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699.  https://doi.org/10.1111/j.1532-5415.2005.53221.x CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory comprehensive assessment of psychopathology in dementia. Neurology 44:2308–2314CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Nutt J (1999) A unified dyskinesias s rating scale for L-dopa-induced dyskinesias? Mov Disord 14(Suppl 1):74PubMedGoogle Scholar
  38. 38.
    Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. San Antonio, TX, p 78204Google Scholar
  39. 39.
    Schneider H, Esbitt S, Gonzalez JS (2013) Hamilton anxiety rating scale. Encyclopedia of behavioral medicine. Springer, New York, pp 886–887Google Scholar
  40. 40.
    Peto V, Jenkinson C, Fitzpatrick R (1998) PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures. J Neurol 245:S10–S14CrossRefPubMedGoogle Scholar
  41. 41.
    Novak M, Guest C (1989) Application of a multidimensional caregiver burden inventory. Gerontologist 29:798–803CrossRefPubMedGoogle Scholar
  42. 42.
    Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B (1994) Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94:182–188.  https://doi.org/10.1053/ai.1994.v94.a54939 CrossRefPubMedGoogle Scholar
  43. 43.
    Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PMM (2003) On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 12(4):349–362CrossRefPubMedGoogle Scholar
  44. 44.
    Sullivan GM, Feinn R (2012) Using effect size—or why the P value is not enough. J Grad Med Educ 4(3):279–282CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Lutz SG, Holmes JD, Ready EA, Jenkins ME, Johnson AM (2016) Clinical presentation of anxiety in Parkinson’s Disease: a scoping review. OTJR (Thorofare N J) 36:134–147.  https://doi.org/10.1177/1539449216661714 CrossRefGoogle Scholar
  46. 46.
    Yamanishi T, Tachibana H, Oguru M, Matsui K, Toda K, Okuda B et al (2013) Anxiety and depression in patients with Parkinson’s disease. Intern Med 52:539–545.  https://doi.org/10.2169/internalmedicine.52.8617 CrossRefPubMedGoogle Scholar
  47. 47.
    Prakash KM, Nadkarni NV, Lye WK, Yong MH, Tan EK (2016) The impact of non-motor symptoms on the quality of life of Parkinson’s disease patients: a longitudinal study. Eur J Neurol 23:854–860.  https://doi.org/10.1111/ene.12950 CrossRefPubMedGoogle Scholar
  48. 48.
    Berganzo K, Tijero B, González-Eizaguirre A, Somme J, Lezcano E, Gabilondo I et al (2016) Motor and non-motor symptoms of Parkinson’s disease and their impact on quality of life and on different clinical subgroups. Neurologia 31:585–591.  https://doi.org/10.1016/j.nrl.2014.10.010 CrossRefPubMedGoogle Scholar
  49. 49.
    Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR (2016) Medication therapy management service for patients with Parkinson’s disease: a before-and-after study. Neurol Ther 5:85–99.  https://doi.org/10.1007/s40120-016-0046-4 CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Carter JH, Stewart BJ, Archbold PG, Parkinson’s Study Group et al (1998) Living with a person who has Parkinson’s disease: the spouse’s perspective by stage of disease. Mov Disord 13:20–28.  https://doi.org/10.1002/mds.870130108 CrossRefPubMedGoogle Scholar
  51. 51.
    Ozdilek B, Gunal DI (2012) Motor and non-motor symptoms in Turkish patients with Parkinson’s disease affecting family caregiver burden and quality of life. J Neuropsychiatry Clin Neurosci 24:478–483.  https://doi.org/10.1176/appi.neuropsych.11100315 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Rosella Ciurleo
    • 1
    Email author
  • Francesco Corallo
    • 1
  • Lilla Bonanno
    • 1
  • Viviana Lo Buono
    • 1
  • Giuseppe Di Lorenzo
    • 1
  • Roberta Versaci
    • 1
  • Cettina Allone
    • 1
  • Rosanna Palmeri
    • 1
  • Placido Bramanti
    • 1
  • Silvia Marino
    • 1
    • 2
  1. 1.IRCCS Centro Neurolesi “Bonino-Pulejo”MessinaItaly
  2. 2.Department of Biomedical and Dental Sciences and Morphological and Functional ImagingUniversity of MessinaMessinaItaly

Personalised recommendations